SAB Biotherapeutics (SABS) PT Lowered to $12 at Chardan Capital Markets Aug 8, 2025 08:23AM
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes Nov 14, 2023 07:30AM
SAB Biotherapeutics (SABS) Announces Private Placement of up to $130 Million Oct 2, 2023 07:31AM
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes Oct 2, 2023 07:30AM
Chardan Capital Markets Starts SAB Biotherapeutics (SABS) at Buy Nov 5, 2021 08:03AM


Oct 25, 2021 07:39AM SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
Oct 25, 2021 07:39AM SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company